80 FR 50858 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 162 (August 21, 2015)

Page Range		50858-50859
FR Document		2015-20694

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 80 Issue 162 (Friday, August 21, 2015)

[Federal Register Volume 80, Number 162 (Friday, August 21, 2015)]
[Notices]
[Pages 50858-50859]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-20694]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other 
Mental Disorders

    Description of Technology: Dopamine is a neurotransmitter that 
exerts important effects on locomotor activity, motivation and reward, 
and cognition. The dopamine transporter (DAT) is expressed on the 
plasma membrane of dopamine synthesizing neurons, and is responsible 
for clearing dopamine released into the extra-cellular space, thereby 
regulating neurotransmission. The dopamine transporter plays a 
significant role in neurotoxicity and human diseases, such as 
Parkinson's disease, drug abuse (especially cocaine addiction), 
Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder 
(ADD/ADHD), and a number of other CNS disorders. Therefore, the 
dopamine transporter is a strong target for research and the discovery 
of potential therapeutics for the treatment of these indications.
    This invention discloses novel benztropine analogs and methods of 
using these analogs for treatment of mental and conduct disorders such 
as cocaine abuse, narcolepsy, ADHD, obesity and nicotine abuse. The 
disclosed analogs are highly selective and potent inhibitors of DAT, 
but without an apparent cocaine-like behavioral profile. In addition to 
their use as a treatment for cocaine abuse, these compounds have also 
shown efficacy in animal models of ADHD and nicotine abuse, and have 
also been shown to reduce food intake in animals. They may also be 
useful medications for other indications where dopamine-related 
behavior is compromised, such as alcohol addiction, tobacco addiction, 
and Parkinson's disease.
    Potential Commercial Applications:
     Drug leads for treatment of cocaine abuse, ADHD, nicotine 
abuse, obesity, and other dopamine-related disorders
     Imaging probes for dopamine transporter binding sites
    Development Stage: Early-stage; In vitro data available
    Inventors: Amy H. Newman, Mu-fa Zou, Jonathan L. Katz (all of NIDA)
    Intellectual Property: HHS Reference No. E-234-2005/1--US Patent 
No. 8,383,817 issued February 26, 2013
    Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565; 
[email protected]
    Collaborative Research Opportunity: The National Institute on Drug 
Abuse, Medicinal Chemistry and Psychobiology Sections, is seeking 
statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
medications to treat cocaine abuse and addiction. For collaboration 
opportunities please contact John D. Hewes, Ph.D. at 
[email protected].

Novel Dopamine Receptor Ligands as Therapeutics for Central Nervous 
System Disorders

    Description of Technology: The dopamine D3 receptor subtype is a 
member of the dopamine D2 subclass of receptors. These receptors have 
been implicated in a number of CNS disorders, including psychostimulant

[[Page 50859]]

abuse, psychosis and Parkinson's disease. Compounds that bind with high 
affinity and selectivity to D3 receptors can not only provide important 
tools with which to study the structure and function of this receptor 
subtype, but may also have therapeutic potential in the treatment of 
numerous psychiatric and neurologic disorders.
    The 4-phenylpiperazine derivatives are an important class of 
dopamine D3 selective ligands. However, due to their highly lipophilic 
nature, these compounds suffer from solubility problems in aqueous 
media and reduced bioavailability. To address this problem, a process 
was designed to introduce functionality into the carbon chain linker of 
these compounds. Compared to currently available dopamine D3 receptor 
ligands, the resulting compounds show improved pharmacological 
properties and D3 selectivities but due to their more hydrophilic 
nature, these derivatives are predicted to have improved water 
solubility and bioavailability.
    Potential Commercial Applications:
     Therapeutics for a variety of psychiatric and neurologic 
disorders
     Research tools to study D3 receptor structure and function
    Competitive Advantages:
     Improved pharmacological properties and selectivity over 
existing dopamine D3 receptor ligands
     Hydrophilic nature likely to lead to improved water 
solubility and bioavailability
    Development Stage: Early-stage; In vitro data available
    Inventors: Amy H. Newman (NIDA), Peter Grundt (NIDA), Jianjing Cao 
(NIDA), Robert Luedtke
    Intellectual Property: HHS Reference No. E-128-2006/0--US Patent 
No. 8,748,608 issued June 10, 2014
    Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565; 
[email protected]
    Collaborative Research Opportunity: The National Institute on Drug 
Abuse, Medications Discovery Research Branch, is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize 4-
phenylpiperazine derivatives as dopamine D3 selective ligands. For 
collaboration opportunities, please contact Vio Conley, M.S. at 240-
276-5531 or [email protected].

Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed 
Paraffin-Embedded Single Cells

    Description of Technology: A method of detecting DNase I 
hypersensitive sites ((DHS) in a single cell or very small number of 
cells, including cells recovered from formalin-fixed paraffin-embedded 
(FFPE) tissue slides of patient samples. DHS has revealed a large 
number of potential regulatory elements for transcriptional regulation 
in various cell types. The application of DNase-Seq techniques to 
patient samples can elucidate pathophysiological mechanisms of gene 
function in a variety of diseases as well as provide potentially 
important diagnostic and prognostic information. Unfortunately, the 
current DNase-Seq techniques require large number of cells and are 
applicable only to larger biopsies and surgical specimens. This 
technique, called Pico-Seq, allows detection when only very small 
population of cells are available, such as rare primary tumor cells and 
circulating-tumor-cells, isolated by a variety of methods. Pico-Seq 
uses conditions capable of restoring the DNase I sensitivity, similar 
to native/fresh cells, in tissue/cells from slides processed by 
extremely harsh conditions, such as in FFPE tissues.
    Potential Commercial Applications:
     Diagnostic and prognostic kits
     Research kits
    Competitive Advantages:
     Applicable to very small number of cells down to a single 
cell.
     Capable of using cells isolated by any of the available 
methods, including flow cytometry, biopsies, laser capture 
microdissection, and even cells recovered from formalin-fixed paraffin-
embedded tissue slides of patient samples.
    Development Stage: Early-stage; In vitro data available
    Inventors: Keji Zhao and Tang Qingsong (NHLBI)
    Intellectual Property: HHS Reference No. E-254-2014/0--US 
Provisional Application No. 62/118,574 filed February 20, 2015
    Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-
435-4507; [email protected]

    Dated: August 18, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-20694 Filed 8-20-15; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 162 / Friday, August 21, 2015 / Notices 50859

abuse, psychosis and Parkinson’s number of cells, including cells amended (5 U.S.C. App.), notice is
disease. Compounds that bind with high recovered from formalin-fixed paraffin- hereby given of the following meetings.
affinity and selectivity to D3 receptors embedded (FFPE) tissue slides of The meetings will be closed to the
can not only provide important tools patient samples. DHS has revealed a public in accordance with the
with which to study the structure and large number of potential regulatory
provisions set forth in sections
function of this receptor subtype, but elements for transcriptional regulation
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
may also have therapeutic potential in in various cell types. The application of
DNase-Seq techniques to patient as amended. The grant applications and
the treatment of numerous psychiatric
and neurologic disorders. samples can elucidate the discussions could disclose
The 4-phenylpiperazine derivatives pathophysiological mechanisms of gene confidential trade secrets or commercial
are an important class of dopamine D3 function in a variety of diseases as well property such as patentable material,
selective ligands. However, due to their as provide potentially important and personal information concerning
highly lipophilic nature, these diagnostic and prognostic information. individuals associated with the grant
compounds suffer from solubility Unfortunately, the current DNase-Seq applications, the disclosure of which
problems in aqueous media and reduced techniques require large number of cells would constitute a clearly unwarranted
bioavailability. To address this problem, and are applicable only to larger invasion of personal privacy.
a process was designed to introduce biopsies and surgical specimens. This Name of Committee: National Cancer
functionality into the carbon chain technique, called Pico-Seq, allows Institute Special Emphasis Panel; NCI P01
linker of these compounds. Compared to detection when only very small Meeting II.
currently available dopamine D3 population of cells are available, such as Date: October 15–16, 2015.
receptor ligands, the resulting rare primary tumor cells and Time: 8:00 p.m. to 5:00 p.m.
compounds show improved circulating-tumor-cells, isolated by a Agenda: To review and evaluate grant
pharmacological properties and D3 variety of methods. Pico-Seq uses applications.
selectivities but due to their more conditions capable of restoring the Place: Hyatt Regency Bethesda, One
hydrophilic nature, these derivatives are DNase I sensitivity, similar to native/ Bethesda Metro Center, 7400 Wisconsin
predicted to have improved water fresh cells, in tissue/cells from slides Avenue, Bethesda, MD 20814.
solubility and bioavailability. processed by extremely harsh Contact Person: Delia Tang, MD, Scientific
Potential Commercial Applications: conditions, such as in FFPE tissues. Review Officer, Research Programs Review
• Therapeutics for a variety of Potential Commercial Applications: Branch, Division of Extramural Activities,
psychiatric and neurologic disorders • Diagnostic and prognostic kits National Cancer Institute, NIH, 9609 Medical
• Research tools to study D3 receptor • Research kits
Center Drive, Room 7W602, Bethesda, MD
structure and function Competitive Advantages:
20892, 240–276–6456, tangd@mail.nih.gov
Competitive Advantages: • Applicable to very small number of
cells down to a single cell. Name of Committee: National Cancer
• Improved pharmacological
properties and selectivity over existing • Capable of using cells isolated by Institute Initial Review Group; Subcommittee
any of the available methods, including I-Transition to Independence.
dopamine D3 receptor ligands Date: October 20–21, 2015.
• Hydrophilic nature likely to lead to flow cytometry, biopsies, laser capture
microdissection, and even cells Time: 8:00 a.m. to 1:00 p.m.
improved water solubility and Agenda: To review and evaluate grant
bioavailability recovered from formalin-fixed paraffin-
embedded tissue slides of patient applications.
Development Stage: Early-stage; In Place: Hilton Alexandria Old Town, 1767
vitro data available samples.
Development Stage: Early-stage; In King Street, Alexandria, VA 22314.
Inventors: Amy H. Newman (NIDA),
Peter Grundt (NIDA), Jianjing Cao vitro data available Contact Person: Sergei Radaev, Ph.D.
Inventors: Keji Zhao and Tang Scientific Review Officer, Resources and
(NIDA), Robert Luedtke
Qingsong (NHLBI) Training Review Branch, Division of
Intellectual Property: HHS Reference
Intellectual Property: HHS Reference Extramural Activities, National Cancer
No. E–128–2006/0—US Patent No.
No. E–254–2014/0—US Provisional Institute, NIH, 9609 Medical Center Drive,
8,748,608 issued June 10, 2014 Application No. 62/118,574 filed
Licensing Contact: Betty B. Tong, Room 7W114, Bethesda, MD 20892, 240–
February 20, 2015 276–6466, sradaev@mail.nih.gov.
Ph.D.; 301–594–6565; tongb@ Licensing Contact: Cristina
mail.nih.gov (Catalogue of Federal Domestic Assistance
Thalhammer-Reyero, Ph.D., M.B.A.; Program Nos. 93.392, Cancer Construction;
Collaborative Research Opportunity: 301–435–4507; ThalhamC@mail.nih.gov
The National Institute on Drug Abuse, 93.393, Cancer Cause and Prevention
Medications Discovery Research Dated: August 18, 2015. Research; 93.394, Cancer Detection and
Branch, is seeking statements of Richard U. Rodriguez, Diagnosis Research; 93.395, Cancer
capability or interest from parties Acting Director, Office of Technology Treatment Research; 93.396, Cancer Biology
interested in collaborative research to Transfer, National Institutes of Health. Research; 93.397, Cancer Centers Support;
further develop, evaluate, or [FR Doc. 2015–20694 Filed 8–20–15; 8:45 am] 93.398, Cancer Research Manpower; 93.399,
commercialize 4-phenylpiperazine BILLING CODE 4140–01–P Cancer Control, National Institutes of Health,
derivatives as dopamine D3 selective HHS)
ligands. For collaboration opportunities, Dated: August 17, 2015.
please contact Vio Conley, M.S. at 240– DEPARTMENT OF HEALTH AND Melanie J. Gray,
276–5531 or conleyv@mail.nih.gov. HUMAN SERVICES
rmajette on DSK7SPTVN1PROD with NOTICES

Program Analyst, Office of Federal Advisory
Genome Wide DNase I Hypersensitive National Institutes of Health Committee Policy.
Sites Detection in Formalin-Fixed [FR Doc. 2015–20642 Filed 8–20–15; 8:45 am]
Paraffin-Embedded Single Cells National Cancer Institute; Notice of BILLING CODE 4140–01–P
Closed Meetings
Description of Technology: A method
of detecting DNase I hypersensitive sites Pursuant to section 10(d) of the
((DHS) in a single cell or very small Federal Advisory Committee Act, as

VerDate Sep<11>2014 15:07 Aug 20, 2015 Jkt 235001 PO 00000 Frm 00041 Fmt 4703 Sfmt 9990 E:\FR\FM\21AUN1.SGM 21AUN1

Document Created: 2018-02-23 11:01:07
Document Modified: 2018-02-23 11:01:07

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402- 0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
FR Citation		80 FR 50858

80 FR 50858 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 162 (August 21, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health